Xellia Pharmaceuticals APS
16 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
5
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 30, 2026The maintenance fee for Method for treatment of lung infections by administration of aminoglycosides by aerolisation (US 9,067,032) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
- 1 fee due Mar 15, 2027The maintenance fee for Method for purification of Micafungin (US 9,132,163) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 1 fee due Apr 6, 2027The maintenance fee for Process for purifying lipopeptides (US 9,150,894) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
- 1 fee due Jul 14, 2027The maintenance fee for Sulfomethylated polymixin compositions (US 10,532,080) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
- 1 fee due Sep 1, 2027The maintenance fee for 2-amino-3-methyl-hex-5-enoic acid and its use in the production of peptides including bacitracins (US 9,272,983) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Polymyxins, compositions, methods of making and methods of use (US 10,640,536) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,919,470 | Glycopeptide composition with improved antibiotic activity In force · From the USPTO record | In force | From the USPTO record | |
| US 7,981,859 | Glycopeptide Composition with Improved Antibiotic Activity In force · High confidence | In force | High confidence | |
| US 8,163,872 | Purification of glycopeptides In force · From the USPTO record | In force | From the USPTO record | |
| US 8,268,963 | Process for the purification of macrolide antibiotics In force · From the USPTO record | In force | From the USPTO record | |
| US 8,410,044 | Bacitracin antibiotics In force · From the USPTO record | In force | From the USPTO record | |
| US 9,005,990 | Method for purification of colistin and purified colistin components In force · High confidence | In force | High confidence | |
| US 9,150,894 | Process for purifying lipopeptides In force · From the USPTO record | In force | From the USPTO record | |
| US 9,067,032 | Method for treatment of lung infections by administration of aminoglycosides by aerolisation In force · From the USPTO record | In force | From the USPTO record | |
| US 9,272,983 | 2-amino-3-methyl-hex-5-enoic acid and its use in the production of peptides including bacitracins In force · From the USPTO record | In force | From the USPTO record | |
| US 8,598,131 | Method for treatment of lung infections by administration of aminoglycosides by aerolisation In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 19: 16 patents in force now held by others · 3 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 1 abandoned · 5 no status recorded